期刊文献+

氟伐他汀对肾衰大鼠肾脏纤维化病变进展影响及机制探讨 被引量:14

The Effects and Mechanism of Fluvastatin on Renal Fibratic Rats
在线阅读 下载PDF
导出
摘要 目的 :探讨丙戊二酸辅酶A(HMG -CoA)还原酶抑制剂 -氟伐他汀 (Fluvastatin)在慢性进展性肾小球硬化和肾小管间质纤维化过程中对肾血管损伤、肾脏细胞外基质产生和降解过程中的影响。方法 :采用 5 / 6肾切除SD大鼠制备肾小球硬化及慢性肾衰实验动物模型 ,予氟伐他汀治疗后分别于治疗开始、治疗后第 4周、第 8周时间点观察大鼠血脂、尿蛋白、肾功能及血压变化 ,并评价该药对肾小球及小管间质组织病理学变化的干预作用。结果 :氟伐他汀可降血压、减少蛋白尿、降低血脂、改善肾功能、防止和逆转肾血管硬化、狭窄。并通过影响PAI- 1uPA等因子的表达而阻抑肾脏细胞外基质的产生 ,促进其降解。结论 Objective: To investigate the effects of Fluvastatin on renal vascular lesions and production and degradation of extracellular matix(ECM) during the evolution of glomerulosclerosis and tubulointerstitial fibrosis.Methods:5/6 nephrectomized SD rats were used as experimental model.At different time points after being treated with Fluvastatin,serum and urinary biochemical parameters, renal function and blood pressure were measured respectively. The effects of this agent on renal lesions were estimated by PAS and immunohistochemical staining.Results:Blood pressure,proteinuria, hyperlipidemia and renal function were improved significantly in treated group. The PAS staining showed that renal parenchymal and vascular damages improved markedly. The results of immunohistochenical staining showed that protein expression of PAI-1 in renal tissues decreased and uPA expression increased in the treated group.Conclusion: Fluvastatin has an important effect to improve the glomerulosclerosis and tubulointerstitial fibrosis.
出处 《中国中西医结合肾病杂志》 2001年第6期321-324,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 山西省卫生厅 85攻关资助项目(№ .982 1)
关键词 肾切除 肾小球硬化 肾小管间质纤维化 氟伐他汀 肾功能衰竭 nephrectomy rats Glomerulosclerosis Tubulointerstitial fibrosis Fluvastatin
  • 相关文献

参考文献10

  • 1Hamagnochi A, Kims, Warikubchi H, et al, Angiotensin-ⅡandCa2+-blockers prevent gllamerular phenotypic changes in remnant kidney moldel,J Am Soc Nephrd,1996,7:687-693.
  • 2Eddy AA, Lin E, MeCulloch L, et al, Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis and proteolytic cascades, Kid Ind, 1998,53:1182-1189.
  • 3Oda H, Kenne W, et al. Lipids in progression of renal disease, Kid Int, 1997,52 (Suppl 62): 36-38.
  • 4Levy RI, Troendle AJ, Fattu JM, et al, Aquarter century of drug treatment of dyblipoproteinemia, with a focus on the new HMG-coA reductase inhiitor fluvastatin,Circulation,1998,87(4):45-53.
  • 5Knopp RH, Frohich J, Jokubaitis LA, et al, Efficacy and safety of fluvastatin in patients with non-insulin dependent diabetes mellitus and hyperlipidemia, Am J Med, 1994, 96(Suppl6A): 69-78.
  • 6Dallongeville J, Fruchart JC, Plister P, et al, Fluvastatin reduces levels of plasma apo-B-containing particles and increase those of LpA-1, Am J med, 1994,96 (suppl6 A):32-36.
  • 7Eddy AA, et al, Molecular insights into renal interstitial fibrosis, J Am Soc Nephrol, 1996,7:2495-2508.
  • 8Diamond JR, et al, Effect of lipid abnormalities on the progression of renal damage, analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis, Kid Int, 1991,39(Suppl31):29-34.
  • 9Ttnad E, Parthasarathy S, Sambrano GR, et al, A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purifrcution and role in recognition of oxidatively damaged cells, Proc Natl Acad Sci USA, 1995,92:1391-1395.
  • 10Samuelsson O, Knight-Gibson C, Larsson R, et al, Different action of triglyceride-rich and cholesterol-rich apoB-containing lipoproteins on progression of renal failure,J Am Soc Nephrol, 1996,7:1324.

同被引文献157

引证文献14

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部